Patent 10314792 was granted and assigned to Zynerba Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.
The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.